BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29417826)

  • 1. Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
    Famiglini V; Silvestri R
    Antivir Chem Chemother; 2018; 26():2040206617753443. PubMed ID: 29417826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.
    Xu S; Song S; Sun L; Gao P; Gao S; Ma Y; Kang D; Cheng Y; Zhang X; Cherukupalli S; De Clercq E; Pannecouque C; Liu X; Zhan P
    Bioorg Med Chem; 2022 Jan; 53():116531. PubMed ID: 34890994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
    La Regina G; Coluccia A; Brancale A; Piscitelli F; Gatti V; Maga G; Samuele A; Pannecouque C; Schols D; Balzarini J; Novellino E; Silvestri R
    J Med Chem; 2011 Mar; 54(6):1587-98. PubMed ID: 21366296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
    Piscitelli F; Coluccia A; Brancale A; La Regina G; Sansone A; Giordano C; Balzarini J; Maga G; Zanoli S; Samuele A; Cirilli R; La Torre F; Lavecchia A; Novellino E; Silvestri R
    J Med Chem; 2009 Apr; 52(7):1922-34. PubMed ID: 19281225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.
    Zhao T; Meng Q; Kang D; Ji J; De Clercq E; Pannecouque C; Liu X; Zhan P
    Eur J Med Chem; 2019 Nov; 182():111619. PubMed ID: 31434039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Clotet B; Esté JA; Cirilli R; Novellino E; Silvestri R
    Eur J Med Chem; 2014 Jun; 80():101-11. PubMed ID: 24769348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
    La Regina G; Coluccia A; Brancale A; Piscitelli F; Famiglini V; Cosconati S; Maga G; Samuele A; Gonzalez E; Clotet B; Schols D; Esté JA; Novellino E; Silvestri R
    J Med Chem; 2012 Jul; 55(14):6634-8. PubMed ID: 22712652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
    Gao P; Song S; Frutos-Beltrán E; Li W; Sun B; Kang D; Zou J; Zhang J; Pannecouque C; De Clercq E; Menéndez-Arias L; Zhan P; Liu X
    Bioorg Med Chem; 2021 Jan; 30():115927. PubMed ID: 33352387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.
    Huang B; Wang X; Liu X; Chen Z; Li W; Sun S; Liu H; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Bioorg Med Chem; 2017 Aug; 25(16):4397-4406. PubMed ID: 28659246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of interaction of novel indolylarylsulfone derivatives with K103N and Y181I mutant HIV-1 reverse transcriptase in complex with its substrates.
    Samuele A; Bisi S; Kataropoulou A; La Regina G; Piscitelli F; Gatti V; Silvestri R; Maga G
    Antivir Chem Chemother; 2011 Nov; 22(3):107-18. PubMed ID: 22095519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Famiglini V; La Regina G; Coluccia A; Pelliccia S; Brancale A; Maga G; Crespan E; Badia R; Riveira-Muñoz E; Esté JA; Ferretti R; Cirilli R; Zamperini C; Botta M; Schols D; Limongelli V; Agostino B; Novellino E; Silvestri R
    J Med Chem; 2014 Dec; 57(23):9945-57. PubMed ID: 25418038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
    Nalli M; Armijos Rivera JI; Masci D; Coluccia A; Badia R; Riveira-Muñoz E; Brambilla A; Cinquina E; Turriziani O; Falasca F; Catalano M; Limatola C; Esté JA; Maga G; Silvestri R; Crespan E; La Regina G
    Eur J Med Chem; 2020 Dec; 208():112696. PubMed ID: 32883642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Silvestri R; Artico M; De Martino G; La Regina G; Loddo R; La Colla M; Mura M; La Colla P
    J Med Chem; 2004 Jul; 47(15):3892-6. PubMed ID: 15239667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126.
    Silvestri R; Artico M; Bruno B; Massa S; Novellino E; Greco G; Marongiu ME; Pani A; De Montis A; La Colla P
    Antivir Chem Chemother; 1998 Mar; 9(2):139-48. PubMed ID: 9875385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
    Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
    Huang B; Li C; Chen W; Liu T; Yu M; Fu L; Sun Y; Liu H; De Clercq E; Pannecouque C; Balzarini J; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 92():754-65. PubMed ID: 25626145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in the Design and Development of Non-nucleoside Reverse Transcriptase Inhibitor Scaffolds.
    Shirvani P; Fassihi A; Saghaie L
    ChemMedChem; 2019 Jan; 14(1):52-77. PubMed ID: 30417561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
    Regina GL; Coluccia A; Piscitelli F; Bergamini A; Sinistro A; Cavazza A; Maga G; Samuele A; Zanoli S; Novellino E; Artico M; Silvestri R
    J Med Chem; 2007 Oct; 50(20):5034-8. PubMed ID: 17803291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
    Sergeyev S; Yadav AK; Franck P; Michiels J; Lewi P; Heeres J; Vanham G; Ariën KK; Vande Velde CM; De Winter H; Maes BU
    J Med Chem; 2016 Mar; 59(5):1854-68. PubMed ID: 26785139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.